Kate R. Secombe

856 total citations
21 papers, 607 citations indexed

About

Kate R. Secombe is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Kate R. Secombe has authored 21 papers receiving a total of 607 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Pulmonary and Respiratory Medicine and 12 papers in Oncology. Recurrent topics in Kate R. Secombe's work include Gut microbiota and health (10 papers), Oral health in cancer treatment (9 papers) and Gastric Cancer Management and Outcomes (5 papers). Kate R. Secombe is often cited by papers focused on Gut microbiota and health (10 papers), Oral health in cancer treatment (9 papers) and Gastric Cancer Management and Outcomes (5 papers). Kate R. Secombe collaborates with scholars based in Australia, Netherlands and Iran. Kate R. Secombe's co-authors include Joanne M. Bowen, Hannah R. Wardill, Rachel J. Gibson, Janet K. Coller, Ysabella Van Sebille, Ghanyah Al-Qadami, Richard M. Logan, Bronwen J. Mayo, Dorothy Keefe and Robert V. Bryant and has published in prestigious journals such as International Journal of Cancer, Experimental Biology and Medicine and Molecular Cancer Therapeutics.

In The Last Decade

Kate R. Secombe

20 papers receiving 602 citations

Peers

Countries citing papers authored by Kate R. Secombe

Since Specialization

Citations

This map shows the geographic impact of Kate R. Secombe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate R. Secombe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate R. Secombe more than expected).

Fields of papers citing papers by Kate R. Secombe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate R. Secombe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate R. Secombe. The network helps show where Kate R. Secombe may publish in the future.

Co-authorship network of co-authors of Kate R. Secombe

This figure shows the co-authorship network connecting the top 25 collaborators of Kate R. Secombe. A scholar is included among the top collaborators of Kate R. Secombe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate R. Secombe. Kate R. Secombe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC/ISOO framework 2024 ·Supportive Care in Cancer ·Andrea M. Stringer, (unknown), Rui Amaral Mendes, Nicole M. A. Blijlevens, (unknown), Paul Joyce, (unknown), Alexa M. G. A. Laheij, Giulia Ottaviani, Kate R. Secombe, (unknown), Yehuda Zadik, Paolo Bossi, Hannah R. Wardill	6
2	Ferroptosis – a potential feature underlying neratinib-induced colonic epithelial injury 2024 ·Cancer Chemotherapy and Pharmacology ·(unknown), Susan L. Woods, Kate R. Secombe, (unknown), (unknown), Scott Ayton, John Finnie, (unknown), Normand Pouliot, Joanne M. Bowen	0
3	Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy 2023 ·Cancer Chemotherapy and Pharmacology ·(unknown), Joanne M. Bowen, Rachel J. Gibson, (unknown), Kate R. Secombe, (unknown), Richard M. Logan, Jonathan Tuke, (unknown), (unknown), Christos S. Karapetis, Dorothy Keefe, Janet K. Coller	3
4	Baseline gut microbiota composition is associated with oral mucositis and tumour recurrence in patients with head and neck cancer: a pilot study 2023 ·Supportive Care in Cancer ·Ghanyah Al-Qadami, Joanne M. Bowen, Ysabella Van Sebille, Kate R. Secombe, (unknown), Johan Verjans, Hannah R. Wardill, Hien Le	23
5	Exercise and the gut microbiome: implications for supportive care in cancer 2023 ·Supportive Care in Cancer ·Nicolas H. Hart, Matthew P. Wallen, M. Farley, Darren Haywood, (unknown), Kate R. Secombe, Ria Joseph, Raymond J. Chan, (unknown), Laurien M. Buffart, Tina L. Skinner, Hannah R. Wardill	5
6	Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats 2022 ·Neoplasia ·Kate R. Secombe, (unknown), Anthony Wignall, Emma Bateman, Dorothy Keefe, Joanne M. Bowen	11
7	Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities 2022 ·Microorganisms ·Ghanyah Al-Qadami, Kate R. Secombe, (unknown), Hannah R. Wardill, Joanne M. Bowen	102
8	Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment 2021 ·Cancer Chemotherapy and Pharmacology ·Kate R. Secombe, (unknown), (unknown), Hannah R. Wardill, Rachel J. Gibson, Janet K. Coller, Joanne M. Bowen	6
9	Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols 2021 ·Gut Microbes ·Kate R. Secombe, Ghanyah Al-Qadami, (unknown), Joanne M. Bowen, (unknown), Ysabella Van Sebille, Matthew Snelson, Caitlin S.M. Cowan, Gerard Clarke, Cassandra E. Gheorghe, John F. Cryan, Hannah R. Wardill	53
10	Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability 2021 ·Inflammatory Intestinal Diseases ·(unknown), Joanne M. Bowen, Kate R. Secombe, Janet K. Coller, Maxime François, Wayne R. Leifert, Hannah R. Wardill	4
11	Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome 2020 ·Integrative Cancer Therapies ·Kate R. Secombe, Ysabella Van Sebille, Bronwen J. Mayo, Janet K. Coller, Rachel J. Gibson, Joanne M. Bowen	48
12	Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant 2020 ·Breast Cancer ·Kate R. Secombe, (unknown), (unknown), Anthony Wignall, Dorothy Keefe, Joanne M. Bowen	9
13	The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats 2020 ·Cancer Chemotherapy and Pharmacology ·Bronwen J. Mayo, Kate R. Secombe, Anthony Wignall, Emma Bateman, Daniel Thorpe, Claudio Pietra, Dorothy Keefe, Joanne M. Bowen	20
14	Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients 2019 ·EBioMedicine ·Hannah R. Wardill, Kate R. Secombe, Robert V. Bryant, Mette D. Hazenberg, Samuel P. Costello	52
15	Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model 2018 ·Cancer Chemotherapy and Pharmacology ·Kate R. Secombe, (unknown), (unknown), Anthony Wignall, John Finnie, Dorothy Keefe, Francesca Avogadri-Connors, Elizabeth Olek, (unknown), Susan Moran, Joanne M. Bowen	11
16	The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy‐induced gastrointestinal toxicity 2018 ·International Journal of Cancer ·Kate R. Secombe, Janet K. Coller, Rachel J. Gibson, Hannah R. Wardill, Joanne M. Bowen	61
17	Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report 2016 ·Cancer Chemotherapy and Pharmacology ·Janet K. Coller, Joanne M. Bowen, (unknown), Hannah R. Wardill, Ysabella Van Sebille, (unknown), (unknown), Anthony Wignall, (unknown), Kate R. Secombe, Rachel J. Gibson	9
18	TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea 2016 ·Molecular Cancer Therapeutics ·Hannah R. Wardill, Joanne M. Bowen, Ysabella Van Sebille, Kate R. Secombe, Janet K. Coller, (unknown), Richard M. Logan, Rachel J. Gibson	37
19	Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms 2016 ·Molecular Cancer Therapeutics ·Hannah R. Wardill, Rachel J. Gibson, Ysabella Van Sebille, Kate R. Secombe, Janet K. Coller, (unknown), Jim Manavis, Mark R. Hutchinson, Vasiliki Staikopoulos, Richard M. Logan, Joanne M. Bowen	113
20	A novelin vitroplatform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options 2016 ·Experimental Biology and Medicine ·Hannah R. Wardill, Rachel J. Gibson, Ysabella Van Sebille, Kate R. Secombe, Richard M. Logan, Joanne M. Bowen	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact